Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$456K Buy
3,765
+207
+6% +$23.9K 0.09% 103
2025
Q4
$378K Buy
3,558
+116
+3% +$10.9K 0.07% 116
2025
Q3
$292K Sell
3,442
-1,553
-31% -$128K 0.05% 151
2025
Q2
$399K Buy
4,995
+1,799
+56% +$143K 0.07% 134
2025
Q1
$289K Sell
3,196
-108
-3% -$10.1K 0.06% 170
2024
Q4
$331K Sell
3,304
-425
-11% -$43.8K 0.07% 137
2024
Q3
$426K Buy
3,729
+57
+2% +$6.77K 0.09% 119
2024
Q2
$457K Sell
3,672
-17
-0.5% -$2.19K 0.11% 109
2024
Q1
$490K Buy
3,689
+700
+23% +$86.3K 0.14% 94
2023
Q4
$318K Sell
2,989
-38
-1% -$3.94K 0.1% 120
2023
Q3
$314K Sell
3,027
-7,189
-70% -$775K 0.12% 114
2023
Q2
$1.19M Buy
10,216
+1,468
+17% +$167K 0.38% 59
2023
Q1
$937K Sell
8,748
-405
-4% -$43.7K 0.41% 51
2022
Q4
$1.02M Buy
+9,153
New +$936K 0.47% 51

Other funds holding MRK

Aspen Grove Capital's MRK Position: Q1 2026 in Review

Aspen Grove Capital increased its Merck (MRK) stake by 5.8% in Q1 2026, buying an estimated $23.9K and bringing the position to 3,765 shares worth $456K. The position accounts for 0.09% of the portfolio, ranked #103.

Aspen Grove Capital first reported a position in MRK in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.19M in Q2 2023. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Aspen Grove Capital held 3,765 shares of Merck worth $456K as of Q1 2026.
  • Aspen Grove Capital bought 207 Merck shares in Q1 2026, an estimated $23.9K.
  • Merck made up 0.09% of Aspen Grove Capital's portfolio in Q1 2026, its #103 holding.
  • Aspen Grove Capital first reported a position in Merck in Q4 2022 and has held it in 14 quarters since.
  • Aspen Grove Capital's Merck position peaked at $1.19M in Q2 2023.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Aspen Grove Capital's 13F filing for Q1 2026, filed 14 May 2026.